HEMOTAG CPAS is an award-winning cardiac assessment system. Using AI-supported algorithms originally developed with US NIH, NSF and DoD funding, HEMOTAG analyzes vibrations from heart valves and diagnoses developing heart disease earlier than any other technology available at point of care. HEMOTAG is entering the US market in 2021 with a strong IP portfolio, substantial scientific and clinical evidence and extensive early adopter network. HEMOTAG will enter the primary and urgent care markets, giving health care teams the ability to assess and monitor heart disease progression with tools that so far were reserved for specialized diagnostic centers. Allowing patients to engage their care team far more effectively, drastically reduce cost of care and improve health outcomes and patient satisfaction.